Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novo, Lilly Ad Challenges Cause Discontinued Claims For Compounded GLP-1s

Jun 04 2025

• By Sue Sutter

Climbing a mountain — Novo and Lilly are making progress in their uphill battle against ads for compounded GLP-1 products. (Shutterstock)

Related Content

Drug Advertising: NAD’s Clout In Rx Disputes Rising As It Builds Ties With Social Media Platforms, FDA

Apr 08 2024

ViiV Wants FDA, Not NAD, To Handle Dispute Over Its Dovato HIV Drug Ads

Apr 28 2023

GLP-1 Compounding: Lilly Takes Advertising Complaints To NAD

Jan 30 2025

Compounded GLP-1s For Obesity: Is The Genie Out Of The Bottle?

Feb 11 2025

Lilly Targets Sale Of Repackaged, Redosed Zepbound, Mounjaro In Lawsuit

Apr 07 2025

GLP-1 Compounding: Court Backs US FDA Approach To Managing Drug Shortage List

Mar 10 2025

Related Companies

Novo Nordisk A/S

Eli Lilly and Company

More from Marketing & Advertising

More from Compliance

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window